Vacuum devices reduce rebiopsy rate
The use of ultrasound-guided vacuum-assisted breast biopsy devices should help reduce the need for rebiopsies, researchers in a large multicenter trial reported Monday. The study covered five centers in Canada, the U.S., and Europe and included
The use of ultrasound-guided vacuum-assisted breast biopsy devices should help reduce the need for rebiopsies, researchers in a large multicenter trial reported Monday.
The study covered five centers in Canada, the U.S., and Europe and included results from 13,582 ultrasound-guided biopsies conducted between 1999 and 2003. There were 123 rebiopsies.
The rebiopsy rate ranged from 0.2% to 3.21%, depending on the center. The most common reason for rebiopsy was radiological-pathological discordance. The rebiopsy resulted in a diagnostic change 61% of the time, and in 17% of the cases, led to a diagnosis of cancers missed in the first biopsy.
The single biggest factor influencing the rebiopsy rate was the use of a 14-gauge core needle biopsy device, according to the study. Other factors were dense breasts and BI-RADS ratings of four or five. The size of the lesion was not a significant factor.
Other studies have examined the rebiopsy question but, with smaller patient numbers, did not to have the statistical power of the current study, said presenter N. Duchesne of the University of Ottawa.
Although a 14-gauge biopsy device is less expensive than a vacuum-assisted device, the findings suggested a need for wider use of the vacuum assisted device, Duchesne said.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
